Keytruda + chemotherapy demonstrated superior OS/PFS versus chemotherapy in GEJ cancer indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III KEYNOTE-590 trial evaluating Keytruda in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer demonstrated a significant improvement in overall survival.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality.  It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login